Drug for children with spinal muscular atrophy too expensive, HSE says - (The Irish Times via NewsPoints Desk)

  • The Health Service Executive has determined that the spinal muscle atrophy drug Spinraza is not cost-effective at its current price, The Irish Times reported Friday.

  • The HSE determined that the treatment could carry a cost of 20 million euros over five years, while it was not able to reach an accord with the manufacturer regarding a viable price.

  • The regulator noted that Spinraza would carry a cost of  600 000 euros for the first year and 380 000 euros for each successive year.

  • The HSE stated that it was "obligated to ensure that expenditure of this scale must represent evidence of clinical and cost-effectiveness."

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.